AZ weathers another storm as NICE prepares final blow for Faslodex
This article was originally published in Scrip
Executive Summary
More bad news for AstraZeneca. In a week when the company announced that its investigational antidepressant TC-5214, developed in collaboration with Targacept, failed its first Phase III trial (scripintelligence.com, 7 November 2011), NICE, the health technology appraisal institute for England and Wales, today reiterated its concerns that there was little proof that the company's breast cancer drug Faslodex (fulvestrant) was any better than aromatase inhibitors. The institute has published final draft guidance again rejecting the drug for NHS funding.
You may also be interested in...
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.
Germany Courts Clinical Trials With Regulator Reshuffle & New Federal Ethics Committee
Plans to rejig two regulators’ roles and streamline the ethics committee system have drawn some criticism.